GlaxoSmithKline Pharmaceuticals Limited — PPTs, 09-02-2026: Investor Presentation

Here's a concise, retail-friendly summary:

**Business Performance:** GSK Pharma reported solid Q3 results: Revenue at ₹1023 Cr (+8.1%), PAT at ₹277 Cr (+21.3%), and EBITDA at ₹368 Cr (+26.7%). General Medicines, Specialty, and Pediatric Vaccines were key drivers, leading to 10.5% in-market growth.

**Growth Drivers or Strategy:** Strategic focus areas include strengthening key brands in General Medicines & Established Vaccines, scaling Oncology, and establishing adult immunization (Shingrix).

**Recent Developments:** Shingrix saw significant traction with 50,000 Q3 prescriptions (+80% YoY). Oncology showed momentum after RUBY-1 approval. Digital efforts boosted reach to over 360,000 healthcare professionals.

**Key Financial Metrics:**

* Q3 Revenue: ₹1023 Cr (+8.1% YoY)

* Q3 PAT: ₹277 Cr (+21.3% YoY)

* Q3 EPS: ₹16.36 (+9%)

* Cash: ₹2426 Cr

**Management Commentary / Outlook:** Management highlighted improving profitability via better gross margins and operating leverage. Field productivity increased 11%, boosting cost efficiency. Portfolio transformation and innovation in Oncology and Established Vaccines remain priorities.